GlassScriptPhysician profile
Wan-Yin Chan
NPI 1932391471
$19,356.24
in general payments reported to CMS, 2019-2025
33 companies · $5,787 in 2025
The $5,787 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $987 · 2021: $1,286 · 2022: $1,795 · 2023: $1,808 · 2024: $5,472 · 2025: $5,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,638 · Food and Beverage: $5,832 · Travel and Lodging: $350 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,638.34 |
| Food and Beverage | $5,831.57 |
| Travel and Lodging | $349.73 |
| Education | $246.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $8,973.63 | 2019-2025 | Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $2,593.47 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,625.40 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,600.07 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,372.77 | 2019-2025 | |
| Amgen INC. | $437.47 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $353.42 | 2020-2025 | Xolair |
| Optinose US, INC. | $307.84 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $305.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $246.35 | 2019-2024 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $209.08 | 2019-2023 | |
| Shire North American Group INC | $190.79 | 2019 | |
| Abbvie INC. | $132.26 | 2022-2023 | Rinvoq |
| Grifols USA, LLC | $125.45 | 2022-2025 | Xembify |
| Blueprint Medicines Corporation | $120.40 | 2023 | Ayvakit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $112.05 | 2019-2022 | |
| Kaleo, INC. | $83.57 | 2023-2024 | Auvi-Q |
| Incyte Corporation | $71.39 | 2022-2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $61.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.37 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $53.11 | 2025 | Alvesco |
| Octapharma USA, INC. | $53.06 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $45.45 | 2022 | |
| Leo Pharma INC. | $42.73 | 2022 | |
| Ionis Pharmaceuticals, INC. | $34.40 | 2025 | |
| Greer Laboratories, INC. | $34.14 | 2024 | Palforzia |
| Aimmune Therapeutics, INC. | $21.44 | 2021 | |
| Organon LLC | $21.43 | 2025 | Vtama |
| Hikma Pharmaceuticals USA | $20.76 | 2024 | Ryaltris |
| Horizon Therapeutics Plc | $20.59 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $16.57 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wan-Yin Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.